Sign in
Taking people in South KoreaPhase 1/2

Tests Corabotase for arm stiffness after stroke or brain injury

Tests different doses of Corabotase in adults with arm stiffness.

Key facts

Who runs it
Ipsen
Where
Goyang-si, Incheon, Seongnam-si, and Seoul, South KoreaSee the 4 sitesAlso in 13 other countries, 64 sites
Registry title
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Status
Recruiting
Phase
Phase 1/2
People taking part
240 people, planned
Started
29 Apr 2021
Expected to end
30 Mar 2029
Type of study
Interventional, 3 groups
Treatments tested
  • Corabotase
  • Placebo
  • Dysport
Record updated
28 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stiff, tight arm muscles (spasticity) on one side of the body after a stroke or a traumatic brain injury. It tests IPN10200 (Corabotase) against Dysport and placebo.

Age
18 to 70 years (18 to 65 years for the dose escalation part).
Sex
Men and women can join.
Disease stage
Weakness and spasticity on one side of the body after stroke or traumatic brain injury, at least 6 months ago. Muscle stiffness score (MAS) of 2 or more in the muscle group to be injected, and spasticity angle of 5° or more. No fixed contractures.
Earlier treatment
Never had botulinum toxin (BoNT), or the last BoNT-A or B injection was at least 4 months before the study start. Physiotherapy, occupational therapy, splinting, benzodiazepines and muscle relaxants must stay stable from at least 30 days before the start.

Main reasons for not taking part

  • Disease of the nerve-muscle junction, such as myasthenia gravis or amyotrophic lateral sclerosis
  • Allergy to the study drugs, other botulinum toxins or their ingredients
  • Earlier surgery for spasticity, or phenol or alcohol treatment, in the affected arm
  • Intrathecal baclofen in the 30 days before the start, or planned during the study
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Participant must be 18 to 70 years of age inclusive (except for dose escalation must be 18 to 65 years of age) at the time of signing the informed consent
  • Has spastic hemiparesis following stroke or Traumatic brain injury (TBI)
  • Is at least 6 months post-stroke or TBI
  • Has never received BoNT or if previously treated, should have received their last injection of any commercialized BoNT-A or B at least 4 months prior to study Baseline
  • Has a MAS score ≥2 in the (PTMG) to be injected
  • Is eligible to receive a total recommended dose 1000 U Dysport in the upper limb when applicable
  • Has angle of spasticity ≥5° in the PTMG to be injected
  • Does not have any fixed contractures as defined by:; Complete fingers extension with Angle of arrest at slow speed (Tardieu Scale) (XV1) ≥160°; Complete wrist extension with XV1 ≥90°; Complete elbow extension with XV1 ≥160°
  • Physiotherapy, occupational therapy, splinting, use of benzodiazepine, and muscle relaxants had to be stable from at least 30 days preceding the study Baseline up to the Month 3 visit, and whenever possible until the end of the study
  • In good health (i.e. absence of any uncontrolled systemic disease or other significant medical condition) as determined by medical history, physical and neurological examinations, clinical laboratory studies, electrocardiograms (ECGs), vital signs, and Investigator's judgment prior to randomization
  • Male and female participants Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; Male participants must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception. The participants must agree to use the contraception during the whole period of the study; A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) or is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method (until the end of the study). The investigator should evaluate the potential for contraceptive method failure in relationship to the first dose of study intervention. A WOCBP must have a negative highly sensitive pregnancy test

Who cannot take part

  • Likely treatment with any serotype of BoNT for any condition during the study
  • Undergone previous surgery to treat spasticity in the affected upper limb
  • Has initiated physiotherapy within 30 days prior to Baseline (if physiotherapy initiated more than 30 days prior to Baseline and ongoing, the therapy regimen should be maintained at the same frequency and intensity throughout the study if possible or at least up to 3-months post-injection)
  • Has received previous treatment with phenol and or alcohol in the targeted upper limb any time before the study
  • Has been treated or is likely to be treated with intrathecal baclofen during the 30 days prior to study Baseline or during the course of the study
  • Current or planned treatment with any medications that interfere either directly or indirectly with neuromuscular transmission, such as curare-like non depolarising agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics, within 30 days prior to Baseline
  • Currently planned or a history of tendon lengthening surgery, significant contracture or muscle atrophy at target joint or muscle in the past 6 months prior to Screening
  • Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the half-life is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study
  • Any medical condition (including severe dysphagia or airway disease) that may increase, in the opinion of the investigator, the likelihood of adverse events (AEs) related to BoNT treatment
  • Known disease of the neuromuscular junction (e.g. Lambert-Eaton myasthenic syndrome, myasthenia gravis or amyotrophic lateral sclerosis etc.)
  • Has a history of hypersensitivity to the investigational medicinal products (or other BoNTs) or any excipient used in their formulation
  • Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study
  • Infection at the injection site(s)
  • A history of drug or alcohol abuse
  • Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention, including medications affecting bleeding disorders. For patients taking vitamin K antagonists, the INR values should be controlled (between 2 and 3)
  • Presence of any other condition (e.g. neuromuscular disorder, muscular dystrophies, cancer cachexia, sarcopenia or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgment of the investigator, might increase the risk to the participant or decrease the chance of obtaining satisfactory data to achieve the objectives of the study
  • Pregnant or lactating women, or women of childbearing potential not willing to practice a highly effective form of contraception method at the beginning of the study, for the duration of the study and for the duration of the study
  • Inability to understand protocol procedures and requirements
  • Male participants who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in South Korea

Also in 13 other countries, 64 sites

  • Dongguk University Ilsan HospitalGoyang-si, South KoreaContact: Ipsen Recruitment EnquiriesTaking people
  • The Catholic University of Korea, Incheon St. Mary's HospitalIncheon, South KoreaContact: Ipsen Recruitment EnquiriesTaking people
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Ipsen Recruitment EnquiriesTaking people
  • Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Ipsen Recruitment EnquiriesTaking people

About the trial

What the trial wants to find out

The purpose of the study is to assess the safety and efficacy of increasing doses of Corabotase (also known as IPN10200) with the aim to evaluate the Pharmacodynamics (PD) profile of Corabotase and to establish the total Corabotase doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity.

The 3 groups in the trial

  • Dose escalationTreatment being tested

    One single administration of study medication (Corabotase, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.

    Treatment: Corabotase, Placebo, and Dysport

  • Dose rangingTreatment being tested

    Two fixed doses of Corabotase will be administrated as a single injection into several muscle groups of the upper limb. Participants will be randomised in the ratio of 3:3:2 (total Corabotase dose 1: 30 participants; total Corabotase dose 2: 30 participants; Dysport: 20 participants)

    Treatment: Corabotase and Dysport

  • Total doseTreatment being tested

    One single injection of study medication will be administered locally into several muscle groups of the upper limb. Participants will be randomized in the ratio of 2:1 (Total Corabotase dose: 30 participants; placebo: 15 participants, resulting in a total of 45 participants in Stage 3). Or Participants will be randomized in the ratio of 3:1 (Corabotase lower dose: 30 participants; placebo: 10 participants, then Corabotase higher dose: 30 participants; placebo: 10 participants, resulting in a total of 80 participants in Stage 3).

    Treatment: Corabotase and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.
Plain-language title
Tests Corabotase for arm stiffness after stroke or brain injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04752774, who can take part
Record updated
28 July 2026